Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 62 peer-reviewed journal articles Updated
Hematology

Acquired Idiopathic Sideroblastic Anemia: A Patient's Guide

At a Glance

Acquired Idiopathic Sideroblastic Anemia (AISA), now accurately called MDS-SF3B1, is a slow-moving and manageable blood disorder. Proper diagnosis requires a bone marrow biopsy and genetic testing to rule out reversible causes like copper deficiency.

If you or a loved one has been diagnosed with Acquired Idiopathic Sideroblastic Anemia (AISA), you may be feeling overwhelmed. This resource guide is designed to translate the complex medical data surrounding your diagnosis into clear, actionable information.

You will learn that this condition has had many names over the years—including Refractory Anemia with Ring Sideroblasts (RARS) and, most accurately today, Myelodysplastic Syndrome with mutated SF3B1 (MDS-SF3B1) [1]. More importantly, you will learn that for most people, this is a slow-moving, manageable condition [2].

This guide is broken down into five distinct sections to help you navigate your care:

01

Understanding Your Diagnosis: From AISA to MDS-SF3B1

Learn about acquired idiopathic sideroblastic anemia (AISA), now called MDS-SF3B1. Understand ring sideroblasts, lower-risk MDS, and treatment options.

02

Symptoms and Reversible Causes: Solving the Mystery

Learn about the symptoms and reversible causes of acquired sideroblastic anemia. Discover why copper deficiency, zinc, and medications can mimic MDS.

03

Decoding Your Pathology: The Science of Your Marrow

Learn how to read your MDS-RS and MDS-SF3B1 pathology report. Understand ring sideroblasts, the SF3B1 mutation, blast counts, and what your results mean.

04

Managing Your Anemia: The Standard of Care

Learn about the standard of care for managing anemia in MDS-RS. Understand treatment options like ESAs, luspatercept, transfusions, and managing iron overload.

05

Your Future Outlook: Risk and Monitoring

Learn about the favorable prognosis for MDS-SF3B1 (MDS-RS). Understand how the IPSS-M risk score, co-mutations, and routine monitoring guide your care.

Take this guide one step at a time. Your goal is not to become a doctor, but to become an empowered patient who can ask the right questions and partner effectively with your care team.

Common questions in this guide

What is Acquired Idiopathic Sideroblastic Anemia (AISA)?
AISA is a rare blood condition where the bone marrow has trouble making healthy red blood cells. Today, doctors most often refer to this condition as Myelodysplastic Syndrome with mutated SF3B1 (MDS-SF3B1) based on genetic testing results.
Is Acquired Idiopathic Sideroblastic Anemia a fast-moving disease?
For most people, AISA is a slow-moving and highly manageable condition. Your care team will monitor your symptoms and blood counts over time to guide your specific treatment plan.
What is an IPSS-M score?
The IPSS-M score is a modern risk assessment tool used by hematologists to understand your long-term outlook. It combines your blood counts and genetic test results to help personalize your monitoring and treatment plan.
Can sideroblastic anemia be caused by a vitamin deficiency or medication?
Yes, sideroblastic anemia can sometimes have completely reversible causes. It is important for your doctor to rule out nutritional issues, like a severe copper deficiency, or toxicities from certain medications before confirming an AISA diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the most accurate, up-to-date name for my specific condition based on my bone marrow biopsy and genetic testing?
  2. 2.What is my IPSS-M score, and how does it affect my long-term outlook?
  3. 3.Have we ruled out all reversible causes for my anemia, such as copper deficiency or medication side effects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (2)
  1. 1

    Impact of the International Consensus Classification of myelodysplastic syndromes.

    Zhang Y, Wu J, Xu Z, et al.

    British journal of haematology 2023; (201(3)):443-448 doi:10.1111/bjh.18628.

    PMID: 36575970
  2. 2

    Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).

    Jouzier C, Cherait A, Cony-Makhoul P, et al.

    Transfusion 2022; (62(5)):961-973 doi:10.1111/trf.16884.

    PMID: 35452143

This guide provides educational information about Acquired Idiopathic Sideroblastic Anemia and MDS-SF3B1. It is not a substitute for professional medical advice, diagnosis, or treatment from your hematologist.

Get notified when new evidence is published on Acquired idiopathic sideroblastic anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.